A faculty member at the Medical College of Wisconsin has spun out a new company, RPRD Diagnostics, which says it will help examine genetic profiles of its customers’ patients to determine how they are likely to react to particular drugs.
Milwaukee-based RPRD, which stands for “Right Patient Right Drug,” was publicly unveiled on Monday. Founder and CEO Ulrich Broeckel says he’ll continue to serve as a professor and researcher at MCW, in addition to his duties at the new company.
